Mesoblast Posts $30.3M Ryoncil® Revenue, Slashes Quarterly Cash Burn to $4.1M
MESO sits 57% above its 52-week low of $9.88.
Summary
Mesoblast reported strong financial results for the quarter ended March 31, 2026, with Ryoncil® net revenues reaching US$30.3 million and net operating cash spend significantly reduced to US$4.1 million. The company also reported a robust cash position of US$122 million. This positive financial update, which includes Ryoncil® sales approaching US$100 million since launch, demonstrates growing commercial momentum and improved financial discipline. The report also highlighted several key operational achievements, including achieving patient recruitment targets for a pivotal Phase 3 trial, receiving FDA clearance for new Ryoncil® label extension and registrational trials, and acquiring a new CAR technology platform for enhanced cell therapies. These developments collectively provide strong catalysts and significantly de-risk the company's financial outlook and product pipeline. Traders will closely watch the continued commercial ramp-up of Ryoncil® and progress in the expanded clinical programs.
At the time of this announcement, MESO was trading at $15.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $9.88 to $21.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.